About xilio therapeutics inc - XLO
Xilio Therapeutics, Inc. operates as a biotechnology company. It focuses on harnessing the immune system to achieve deep and durable clinical responses in cancer. The company uses its proprietary geographically precise solutions platform to rapidly engineer novel molecules, including cytokines and other biologics. Xilio Therapeutics was founded by John C. Williams and Ulrich Rodeck in June 2015 and is headquartered in Waltham, MA.
XLO At a Glance
Xilio Therapeutics, Inc.
828 Winter Street
Waltham, Massachusetts 02451
| Phone | 1-857-524-2466 | Revenue | 6.34M | |
| Industry | Pharmaceuticals: Major | Net Income | -58,241,000.00 | |
| Sector | Health Technology | Employees | 64 | |
| Fiscal Year-end | 12 / 2025 | |||
| View SEC Filings |
XLO Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 8.055 |
| Price to Book Ratio | 2.483 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -0.068 |
| Enterprise Value to Sales | 0.623 |
| Total Debt to Enterprise Value | 2.059 |
XLO Efficiency
| Revenue/Employee | 99,125.00 |
| Income Per Employee | -910,015.625 |
| Receivables Turnover | N/A |
| Total Asset Turnover | 0.096 |
XLO Liquidity
| Current Ratio | 2.21 |
| Quick Ratio | 2.21 |
| Cash Ratio | 2.028 |
XLO Profitability
| Gross Margin | 74.086 |
| Operating Margin | -940.18 |
| Pretax Margin | -918.049 |
| Net Margin | -918.049 |
| Return on Assets | -88.243 |
| Return on Equity | -214.023 |
| Return on Total Capital | -226.267 |
| Return on Invested Capital | -167.549 |
XLO Capital Structure
| Total Debt to Total Equity | 46.267 |
| Total Debt to Total Capital | 31.632 |
| Total Debt to Total Assets | 11.456 |
| Long-Term Debt to Equity | 39.516 |
| Long-Term Debt to Total Capital | 27.016 |